Anuh Pharma Ltd
Anuh Pharma Q1 FY24 earnings call: Revenue & Margins
Q1 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q1 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY2024 Operating Revenue: Rs. EBITDA for Q1 FY24: Rs.
From Anuh Pharma Ltd's Q1 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY2024 Operating Revenue: Rs. 161.48 Cr., up 39% YoY from Rs. 116.38 Cr. in Q1 FY2023 (Page 13).
- Q1 FY2024 Operating Profit: Rs. 31.00 Cr., up 26% YoY from Rs. 24.69 Cr. (Page 13).
- PAT for Q1 FY2024: Rs. 11.75 Cr., up 60% YoY from Rs. 7.34 Cr. (Page 13).
- Total revenue for Q1 FY2024: Rs. 164.95 Cr., increased by 40.58% YoY (Page 6).
- Geographical Export Sales (Q1 FY24 vs Q1 FY23):
- Asia decreased from 35% to 29%
- Europe increased from 30% to 31%
- Africa increased from 15% to 34%
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity expansion at L&L site for Corticosteroids manufacturing increased to 12 MTPA (Page 30).
- Capital expansion this year to support targeted 15-20% growth, boosting production capacity alongside market/geographical expansion (Page 6).
- Dedicated 10,000 sq. ft. R&D facility with 16 scientists for new product/process development (Page 28).
- No specific capex amounts or new plant/projects explicitly mentioned or timelines provided in the presentation.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Frequently Asked Questions
What were Anuh Pharma Ltd Q1 FY24 results?
Q1 FY2024 Operating Revenue: Rs. EBITDA for Q1 FY24: Rs.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Capacity expansion at L&L site for Corticosteroids manufacturing increased to 12 MTPA (Page 30). - Capital expansion this year to support targeted 15-20% growth, boosting production capacity alongside market/geographical expansion (Page 6). - Dedicated 10,000 sq.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.